Pancreatic Cancer Research

ResearcherUniversity of MichiganNo recent work listed

Ding Xue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7870-0408; OpenAlex author ID A5023925299. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 3

  1. First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cancer. First author DOI 10.1021/acsptsci.3c00069↗
  2. Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.1c01934↗
  3. The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-1540↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nouri Neamati · 3 shared papers, 2021–2023 · strength 0.51
  2. Joyeeta Roy · 2 shared papers, 2022–2023 · strength 0.38
  3. Yibin Xu · 2 shared papers, 2022–2023 · strength 0.38
  4. Mats E. Ljungman · 2 shared papers, 2021–2023 · strength 0.34
  5. Duxin Sun · 1 shared paper, 2022 · strength 0.17
  6. Amy Shiu Lee · 1 shared paper, 2021 · strength 0.13
  7. Soma Samanta · 1 shared paper, 2021 · strength 0.13
  8. Yuting Kuang · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.